Bitter Medicine Ahead For Drug Companies
Last year, it was hard to find companies with stronger vital signs than the big drugmakers. The portfolio of 10 big U.S. and British drug stocks followed by SG Cowen Securities Corp. jumped 52% vs. a 26% rise in the Standard & Poor's 500-stock index. And it's easy to see why. With record numbers of new products hitting the market--including such blockbusters as Viagra and Lipitor--drug companies have racked up double-digit sales and earnings growth for the past three years.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.